Department of Clinical Neurosciences, Scientific Institute and University Vita-Salute San Raffaele, Milan, Italy.
Neuropsychobiology. 2011;64(3):141-51. doi: 10.1159/000328947. Epub 2011 Jul 29.
Growing clinical evidence in support of the efficacy and safety of sleep deprivation (SD), and its biological mechanisms of action suggest that this technique can now be included among the first-line antidepressant treatment strategies for mood disorders. SD targets the broadly defined depressive syndrome, and can be administered according to several different treatment schedules: total versus partial, single versus repeated, alone or combined with antidepressant drugs, mood stabilizers, or other chronotherapeutic techniques, such as light therapy and sleep phase advance. The present review focuses on clinical evidence about the place of SD in therapy, its indications, dosage and timing of the therapeutic wake, interactions with other treatments, precautions and contraindications, adverse reactions, mechanism of action, and comparative efficacy, with the aim of providing the clinical psychiatrist with an updated, concise guide to its application.
越来越多的临床证据支持睡眠剥夺（SD）的疗效和安全性，以及其作用的生物学机制，表明该技术现在可以被纳入心境障碍的一线抗抑郁治疗策略中。SD 针对广义定义的抑郁综合征，可以根据几种不同的治疗方案进行管理：完全与部分、单次与重复、单独或与抗抑郁药、心境稳定剂或其他时间治疗技术（如光照疗法和睡眠相位提前）联合使用。本综述重点关注关于 SD 在治疗中的地位、适应证、治疗唤醒的剂量和时间、与其他治疗的相互作用、注意事项和禁忌证、不良反应、作用机制以及疗效比较的临床证据，旨在为临床精神科医生提供应用该技术的最新简明指南。
